Investigator
Hongzhang He
CAPTIS DIAGNOSTICS · funded by NCATS
- Companies
- 2
- Grants
- 2
- Non-dilutive funding
- $2.2M
- First award
- Mar 11, 2025
Resolved onto their grants.
Federal awards on file.
Summed across those awards.
On this record.
Companies from this work
Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.
- CAPTIS DIAGNOSTICS39momentum
OncologyGrant-only
- CAPTIS DIAGNOSTICS29momentum
OncologyGrant-only
Grant record
Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.
- R44
Magnetic Lipid Nanoprobe Platform for Rapid, Highly-Efficient, and Cost-Effective Isolation of Extracellular Vesicles from Non-Invasive Bodily Fluids
$1.1MMar 11, 2025NCATSCAPTIS DIAGNOSTICSNIH RePORTER · 11077464 (opens the source filing in a new tab)
- R44
Magnetic Lipid Nanoprobe Platform for Rapid, Highly-Efficient, and Cost-Effective Isolation of Extracellular Vesicles from Non-Invasive Bodily Fluids
$1.1MMar 11, 2025NCATSCAPTIS DIAGNOSTICSNIH RePORTER · 11300972 (opens the source filing in a new tab)
This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources